Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Novel Point-of-Care Platform for Accurate DOAC Quantification

Objectif

MedicQuant ApS is a Danish deep-tech company spun out of Aarhus University in 2019 to address a critical need in emergency medicine: rapid, accurate quantification of small molecules from patient blood samples.
Our initial product addresses a critical unmet need in the treatment of stroke patients who are on Direct Oral Anticoagulants (DOACs).
For these patients, the life-saving thrombolysis therapy cannot be given if DOAC concentrations are too high, due to the elevated risk of fatal intracranial bleeding. Conventional lab tests take over 40 minutes - unacceptable when every 15-minute delay raises mortality 4% and severe disability 7%. Our solution aims to deliver a fast and reliable drug concentrations that empowers clinicians to make safer, faster treatment decisions in these high-stakes scenarios.
Our patent-pending portable platform provides lab-grade accuracy in under ten minutes from a blood sample. A single-use cartridge employs novel flow-front technology, then is read by a stand-alone benchtop instrument, enabling evidence-based management of DOAC strokes within the critical time window. MedicQuant measures individual DOAC levels directly in whole blood, with no sample preparation, via an innovative point-of-care method.
Usability studies at Bispebjerg Hospital (Denmark) and University College London (UK) plus large-scale testing at University Hospital Tübingen (Germany) confirm performance; an instrument is already in use at Bispebjerg Hospital. The technology has won Best Startup (2019), EIT Health MedTech Bootcamp (2020), and an EIC Women-in-TechEU (2023) grant.
By 2030 we aim to embed our test in EU and US stroke guidelines, reach €37 million revenue, and grow to a 41-person team. We will then extend to other DOAC emergencies, additional drug classes - antibiotics, anticancer agents, immunosuppressants - and new regions.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-EIC-2026-ACCELERATOR-02

Voir tous les projets financés au titre de cet appel

Coordinateur

MEDICQUANT APS
Contribution nette de l'UE
€ 2 494 930,38
Adresse
C/O LINE DEBOIS NIELSEN PALLE JUUL-JENSENS BOULEVARD 82
8200 AARHUS N
Danemark
PME
Oui
Région
Danmark Midtjylland Østjylland
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
Aucune donnée